Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
0.6277
-0.0392 (-5.88%)
At close: Nov 20, 2026, 4:00 PM EST
0.6347
+0.0070 (1.12%)
After-hours: Nov 20, 2026, 7:37 PM EST
Allogene Therapeutics Stock Forecast
ALLO's stock price has decreased by -50.18% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 12 analysts polled by S&P Global, Allogene Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.00. The average 1-year stock price forecast is 1,333.81% higher than the current stock price, while the lowest is $4.00 (+537.25%) and the highest is $14 (+2,130.36%).
Price Target: $9.00 (+1,333.81%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $14 | Buy | Reiterates | $14 | +2,130.36% | Nov 10, 2026 |
| Citi | Citi | Buy Maintains $4 | Buy | Maintains | $4 | +537.25% | Nov 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $9 | Buy | Maintains | $9 | +1,333.81% | Nov 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 | Buy | Maintains | $10 | +1,493.12% | Nov 6, 2026 |
| J.P. Morgan | J.P. Morgan | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 17, 2026 |
Financial Forecast
Revenue This Year
3.78M
Revenue Next Year
10.61M
from 3.78M
Increased by 180.53%
EPS This Year
-0.58
from -0.85
EPS Next Year
-0.61
from -0.58
EPS and Forward PE are based on non-GAAP adjusted numbers.